This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MILTON M. CAHN, M.D.; EDWIN J. LEVY, M.D.; BERTRAM SHAFFER, M.D.

AMA Arch Derm. 1958;78(2):245-246.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The antimalarial drugs quinacrine (Atabrine), chloroquine (Aralen), and hydroxychloroquine (Plaquenil) are effective agents for the prevention and treatment of polymorphous light eruption^1-6 and also for the treatment of discoid lupus erythematosus.^5,7

A new antimalarial compound, amodiaquin (Camoquin), recently has been reported to be equally valuable in the treatment of discoid lupus erythematosus.^8,9

The present study was done to evaluate the effectiveness of this drug in the treatment and suppression of polymorphous light eruption.

Nine patients with a history of recurrent prurigo and plaque-like forms of polymorphous light eruption were studied. These patients had had recurrences of their sunlight-induced eruption each summer, for periods ranging from 6 to 23 years. The eruption had been suppressed in eight of the nine patients during the preceding three summers (1953-1955) by chloroquine. The patients were not given suppressive antimalarial therapy during the spring and early summer of 1956 and were . . . [Full Text PDF of this Article]

Author Affiliations
Philadelphia

From the Department of Dermatology (Dr. Donald M. Pillsbury, Director). University of Pennsylvania School of Medicine.

Footnotes
Submitted for publication Feb. 26, 1958.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?